drugset

drugset / Trial / NCT01239069

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

NCT01239069 ↗

Phase 2 Completed 140 enrolled Santen Inc.

RandomizedParallel-groupSingle-blindTreatment

Summary

Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease

Timeline

Start: 2010-11
Primary completion: 2011-10
Completion: 2011-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DE-110	Unknown	—	Other

Indications